![](https://library.celltelligence.com/wp-content/uploads/2020/07/Precision-Earnings.png)
$0
Precision’s Cash Runway Extended to YE 2024; No Major Clinical Updates; Precision BioSciences Q2 2022 Earnings Call Summary
On Monday, August 8, Precision BioSciences released their Q2 2022 earnings results (press release) highlighting PBCAR0191’s (allogeneic CD19 CAR-T) data readout in June 2022. Of note, no major updates were reported for PBCAR19B (allogeneic stealth CD19 CAR-T) or PBCAR269A (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on PBCAR0191’s potential approval pathway, while discussing potential clinical delays for Precision’s MM programs.